Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., . . . Investigators, N. T. (2023). Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Citación estilo ChicagoBarratt, Jonathan, et al. Results From Part A of the Multi-center, Double-blind, Randomized, Placebo-controlled NefIgArd Trial, Which Evaluated Targeted-release Formulation of Budesonide for the Treatment of Primary Immunoglobulin A Nephropathy. 2023.
Cita MLABarratt, Jonathan, et al. Results From Part A of the Multi-center, Double-blind, Randomized, Placebo-controlled NefIgArd Trial, Which Evaluated Targeted-release Formulation of Budesonide for the Treatment of Primary Immunoglobulin A Nephropathy. 2023.